What is Encorate Chrono used for?

Migraine prophylaxis in adults — FDA-approved 1996 Generalised epilepsy — absence, myoclonic, tonic-clonic seizures (first-line) Focal epilepsy (partial seizures) — alternative to carbamazepine Bipolar disorder — acute mania and maintenance Status epilepticus (IV formulation)

How can I order Encorate Chrono online?

You can order Encorate Chrono online from MedsBase with worldwide shipping. We supply WHO-GMP certified generic medications produced by licensed pharmaceutical manufacturers.

What is the recommended dosage of Encorate Chrono?

Valproate is titrated upward over 2-4 weeks to minimise nausea: Week 1: 500 mg once daily with evening meal Week 2: 750 mg once daily Week 3+: 1,000 mg once daily (target; adjust 500-1,500 mg based on response and tolerance) Assess benefit at 8-12 weeks. Keep a migraine diary to quantify change. ...

Encorate Chrono

Encorate Chrono is sodium valproate 200 / 300 / 400 / 500 / 600 mg extended-release (chrono / CR) tablets from Sun Pharma — once-daily dosing with smoother plasma levels than immediate-release Encorate. For migraine prevention: start 500 mg nightly, titrate to 1,000 mg nightly (range 500-1,500 mg). Same pregnancy and monitoring restrictions as all valproate products.

SKU: N/D Kategoria: Leki przeciwmigrenowe, Przegląd kategorii, Choroby przewlekłe, Zdrowie ogólne, Leczenie migreny Tag: Encorate Chrono, Sodium Valproate, Valproic Acid

✓ Zweryfikowany medycznie przez Morgan Ellis — Badacz farmaceutyczny · 8 lat doświadczenia · Ostatnia weryfikacja: maj 2026

Kup więcej, oszczędź więcej Cena za tabletkę

Wybierz dawkę powyżej, aby wyświetlić ceny opakowań.

Szyfrowana transakcja

Płać kryptowalutą – 10% taniej

Dyskretna dostawa na cały świat

1,400+ klientów · 50+ krajów

Moc

200 mg
300 mg
400 mg
500 mg
600 mg

Ilość

30 tabletek
60 tabletek
90 tabletek
180 tabletek

Wyczyść

⚡ Quick Answer — What is Encorate Chrono?

Encorate Chrono jest 200 / 300 / 400 / 500 / 600 mg sodium valproate / valproic acid extended-release (chrono / CR) tablet from Sun Pharma — an antiepileptic / mood-stabiliser / migraine preventive. In migraine prevention it is used at 500-1,500 mg once daily as a third- or fourth-line preventive after propranolol, topiramate, and amitriptyline. Absolute contraindication in pregnancy and in women of childbearing potential without pregnancy-prevention programme — valproate causes a 10% risk of major congenital malformations (neural tube defects, craniofacial, cardiac, limb, urogenital) and a 30-40% risk of neurodevelopmental impairment (reduced IQ 7-10 points, autism spectrum). The EMA and MHRA have issued progressively stricter prescribing restrictions since 2014. Other important side effects: hepatotoxicity (idiosyncratic; serious rarely fatal), pancreatitis, thrombocytopenia, hyperammonaemia, weight gain, hair loss, tremor, and polycystic ovarian syndrome in women.

Co otrzymujesz z MedsBase: Producent z certyfikatem WHO-GMP · Dyskretne opakowanie · Wysyłka na cały świat · 1,400+ zweryfikowanych opinii klientów

What Is Encorate Chrono?

Encorate Chrono is an oral extended-release (chrono / CR) tablet of sodium valproate / valproic acid 200 / 300 / 400 / 500 / 600 mg from Sun Pharma, supplied in 30-180 tablet packs. Valproate is a branched short-chain fatty acid originally used as a solvent in pharmaceutical chemistry, later serendipitously discovered to have antiepileptic activity. It has been a first-line anticonvulsant for generalised and partial epilepsy since the 1970s and became the third drug with US FDA approval for migraine prophylaxis in 1996 (after propranolol and timolol).

The Chrono / CR extended-release formulation allows once-daily dosing with smoother plasma levels than the immediate-release formulation — better tolerability (less peak-related nausea and tremor) and better adherence.

How Valproate Prevents Migraine

Valproate works through multiple mechanisms relevant to migraine:

GABAergic potentiation — increases GABA synthesis and reduces its degradation, enhancing inhibitory tone in the trigeminal nucleus caudalis and cortex
Suppression of cortical spreading depression — the pathological wave that underlies migraine aura
Voltage-gated sodium-channel blockade — reduces neuronal hyperexcitability
Inhibition of NMDA-glutamate transmission

In migraine-prevention trials (Jensen 1994, Mathew 1995, Klapper 1997), valproate 500-1,500 mg/day reduced monthly migraine frequency by ~50% in about half of treated patients.

Zatwierdzone zastosowania

Profilaktyka migreny u dorosłych — FDA-approved 1996
Padaczka uogólniona — absence, myoclonic, tonic-clonic seizures (first-line)
Focal epilepsy (partial seizures) — alternative to carbamazepine
Zaburzenie afektywne dwubiegunowe — acute mania and maintenance
Stan padaczkowy (IV formulation)

Encorate Chrono Dosage for Migraine Prevention

Valproate is titrated upward over 2-4 weeks to minimise nausea:

Tydzień 1: 500 mg once daily with evening meal
Tydzień 2: 750 mg once daily
Week 3+: 1,000 mg once daily (target; adjust 500-1,500 mg based on response and tolerance)
Oceń korzyści po 8-12 tygodniach. Keep a migraine diary to quantify change.
Therapeutic plasma levels are 50-100 μg/mL for seizure control; for migraine, levels are not routinely needed — dose by clinical response.

Monitorowanie:

Baseline: LFTs (AST, ALT, bilirubin), FBC (platelet count), amylase, pregnancy test (women of childbearing potential), ammonia level (baseline)
Month 1, 3, 6, then 6-monthly: LFTs, FBC
Ammonia check if confusion or new cognitive symptoms

Zaprzestanie stosowania: taper over 2-4 weeks if stopping. In patients with co-existing epilepsy, never stop valproate without neurology input (seizure risk).

⚠️ PREGNANCY WARNING. Valproate is one of the most teratogenic drugs in routine clinical use. First-trimester exposure carries a ~10% risk of major congenital malformations (neural tube defects, heart defects, cleft lip/palate, limb defects, urogenital abnormalities) and a 30-40% risk of neurodevelopmental impairment (reduced childhood IQ by 7-10 points, increased autism spectrum risk 5-fold). Valproate must NOT be used in pregnancy or in women of childbearing potential unless other options have failed and a formal pregnancy-prevention programme is in place. For migraine prevention, switch to propranolol, amitriptyline, or a CGRP antagonist before planning pregnancy.

Działania niepożądane

Bardzo częste (>10%): nausea, dyspepsia, drowsiness, tremor, weight gain, hair thinning / hair loss, alopecia (usually transient; hair regrows after dose reduction or stopping).

Częste (1-10%): ataxia, dizziness, headache, transient elevation of LFTs, thrombocytopenia (usually mild and dose-related), amenorrhoea or irregular menses, polycystic ovarian syndrome (in younger women), decreased libido, peripheral oedema.

Rzadkie, ale poważne:

Hepatotoksyczność — idiosyncratic; typically in first 6 months; risk higher in children under 2, in patients with mitochondrial disorders (POLG mutations are an absolute contraindication), and in polytherapy. Presents as nausea, vomiting, fatigue, jaundice. Requires urgent LFT + discontinuation.
Zapalenie trzustki — rare but potentially fatal; presents with abdominal pain, nausea, vomiting, raised lipase
Encefalopatia hiperamonemiczna — can occur with normal LFTs; presents as confusion, lethargy, new cognitive symptoms
Thrombocytopenia, leukopenia — dose-related; severe forms rare
Zespół Stevensa-Johnsona / toksyczna nekroliza naskórka — rare; stop immediately and seek urgent care

Przeciwwskazania

Pregnancy (absolute) and women of childbearing potential without pregnancy-prevention programme
Known or suspected POLG mitochondrial disorder (and children under 2 where POLG cannot be excluded) — risk of fatal hepatotoxicity
Severe hepatic impairment or family history of severe hepatic dysfunction
Ostra porfiria
Pancreatitis (personal history)
Zaburzenia cyklu mocznikowego
Hypersensitivity to valproate

Karmienie piersią: valproate passes into milk in low amounts (milk/plasma ratio ~0.02). Generally considered acceptable during breastfeeding if the drug is needed; monitor the infant for unusual lethargy or poor feeding.

Interakcje lekowe

Lamotrygina — valproate doubles lamotrigine levels; dose lamotrigine at half the usual starting dose
Antybiotyki karbapenemowe (meropenem, imipenem, ertapenem) — dramatically reduce valproate levels — seizure risk in epilepsy; avoid combination
Warfaryna — valproate displaces warfarin from albumin; monitor INR
Aspiryna — displaces valproate from albumin; raises free valproate concentration
Phenytoin, carbamazepine — reduce valproate levels via CYP induction
Inne depresanty OUN (benzodiazepines, alcohol, opioids) — additive sedation

Przechowywanie

Store below 25°C in original blister. Protect from moisture. Keep out of reach of children.

Najczęściej zadawane pytania

How long until Encorate Chrono starts preventing migraines?

Allow 8-12 weeks at target dose for full effect. Keep a migraine diary recording days per month at baseline and at week 12. A clinically meaningful response is a 50% reduction in monthly migraine days.

Is Encorate Chrono safe if I am planning pregnancy?

Nie. Valproate is one of the most teratogenic drugs in clinical use (~10% malformation risk, 30-40% neurodevelopmental impairment risk). Women of childbearing potential should be switched to a safer preventive (propranolol is preferred in pregnancy) before conception. A 3-month washout is usually recommended before trying to conceive. Valproate should not be used in women planning or able to become pregnant without a formal pregnancy-prevention programme.

Why is the extended-release form different from Encorate IR?

Same molecule (sodium valproate / valproic acid), different release profile. Encorate Chrono is extended-release for once-daily dosing with smoother plasma levels. Better tolerability, better adherence. Encorate IR requires twice-daily dosing.

Will Encorate Chrono make me gain weight?

Yes — weight gain is one of the most common side effects (average 3-5 kg over 6-12 months, more in some). Mechanism includes increased appetite, possibly altered glucose metabolism. If weight gain is problematic, consider switching to topiramat (which causes weight loss) or propranolol (weight-neutral).

Why do I need blood tests on Encorate Chrono?

Valproate can cause hepatotoxicity, pancreatitis, thrombocytopenia, and hyperammonaemia. Baseline + periodic LFTs, full blood count, and clinical monitoring catch problems early. Therapeutic drug monitoring (levels 50-100 μg/mL) is not routinely needed for migraine prevention — dose by clinical response.

Can I drink alcohol on Encorate Chrono?

Avoid regular or heavy alcohol use. Alcohol is additive with valproate’s sedation and adds to hepatic stress. Occasional small amounts are not absolutely contraindicated but regular drinking raises the risk of hepatotoxicity. Alcohol is also a common migraine trigger; reducing intake often improves migraine independent of valproate.

Can I stop Encorate Chrono abruptly?

No — taper over 2-4 weeks. Abrupt discontinuation can trigger rebound migraine and, in patients with any seizure tendency, seizure.

Where can I buy Encorate Chrono online?

You can buy Encorate Chrono (sodium valproate 200 / 300 / 400 / 500 / 600 mg extended-release (chrono / CR) tablet, 30-180 tablet packs) from MedsBase with discreet packaging and worldwide shipping.

Powiązane leki na migrenę w MedsBase

⚕ Zastrzeżenie medyczne. Ta strona ma charakter wyłącznie informacyjny i nie zastępuje porady medycznej wykwalifikowanego pracownika służby zdrowia. Przed rozpoczęciem, zmianą lub przerwaniem przyjmowania jakichkolwiek leków na migrenę zawsze skonsultuj się z lekarzem.

Dlaczego warto zamawiać z MedsBase

📦 Każde zamówienie jest objęte naszą Reshipment Assurance Policy — jeśli Twoja przesyłka nie dotrze w ciągu 20 dni roboczych, wysyłamy ją ponownie.